Daniela Filì

Research Field

We followed the efficacy of long-term lamivudine monotherapy in preventing development of de novo hepatitis B (DNHB) in a large cohort of hepatitis B surface antigen (HBsAg)-negative recipients with grafts from hepatitis B core antibody (HBcAb)-positive donors. Recipients were observed over a long follow-up. Between July 1999 and December 2008, 45 patients (median age 54, range 19-67) who were HBsAg negative before transplantation were included in the study of monoprophylaxis with lamivudine starting on post-operative day 1, and continuing for life. Mean follow-up: 37.9 months; median 32.1 months (range 2.4-117). No suspension of therapy was reported during the study. Post-transplantation, no DNHB was observed in follow-up: all 45 HBsAg-negative recipients remained HBsAg and HBV DNA negative. Thirty-four of these HBsAg-negative recipients were alive at conclusion of the study. A total of 11 patients died, five of HCV recurrence, two of hepatocellular carcinoma (HCC) recurrence, two of disseminated KSV infection, and two of multiorgan failure because of early graft dysfunction. Patient and graft survival of HBsAg-negative recipients with HBcAb-positive donor grafts (45 cases) were not significantly different from those of the HBsAg-negative recipients with HBcAb-negative donor grafts (302 cases). In our experience, lamivudine monoprophylaxis provided complete protection against HBV reactivation and showed long-term efficacy.

10.1111/j.1399-0012.2010.01329.x

Cite

Citations (24)

Model for end stage liver disease for prediction of mortality in people with cirrhosis

Cochrane library (2021)

Gennaro D’Amico Giovanni Perricone Alberto Morabito F Latteri Daniela Filì

Liver disease

10.1002/14651858.cd013849

Cite

Citations (0)

Liver Transplantation Using Donors Older Than 80 Years: A Single-Center Experience

Transplantation Proceedings (2008)

Ioannis Petridis Salvatore Gruttadauria Silvio Nadalin Jacopo Viganò Fabrizio di Francesco

Contraindication

Single Center

Steatosis

Hepatitis C

10.1016/j.transproceed.2008.05.063

Cite

Citations (15)

Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunction

Digestive and Liver Disease (2015)

Daniela Filì Calogero Falletta Angelo Luca Cesar Hernandez Baravoglia Francesco Clemenza

Pulmonary wedge pressure

Cardiac index

10.1016/j.dld.2015.08.014

Cite

Citations (27)

Human herpesvirus 8 infection (HHV-8) in liver transplant (LT) recipients: An emergent fatal complication

Digestive and Liver Disease (2007)

Giada Pietrosi Daniela Filì Giovanni Vizzini V. Lamonaca Giovanna Panarello

Human herpesvirus 6

Herpesviridae Infections

Antiviral Therapy

10.1016/j.dld.2007.07.012

Cite

Citations (1)

ACUTE VOLUME EXPANSION AND TIPS FAILS TO INDUCE CHANGES OF IMPENDING HEART FAILURE IN PATIENTS WITH REFRACTORY ASCITES

Daniela Filì Calogero Falletta Cesar Hernandez Baravoglia Roberto Miraglia Giovanni Vizzini

Refractory (planetary science)

Volume expansion

Source

Cite

Citations (0)

The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real‐life experience

Liver International (2017)

Silvia Martini Maria Francesca Donato Chiara Mazzarelli Maria Rendina Ubaldo Visco‐Comandini

This study aimed to assess the real-life clinical and virological outcomes of HCV waitlisted patients for liver transplantation (LT) who received sofosbuvir/ribavirin (SOF/R) within the Italian compassionate use program.Clinical and virological data were collected in 224 patients with decompensated cirrhosis and/or hepatocellular carcinoma (HCC) receiving daily SOF/R until LT or up a maximum of 48 weeks.Of 100 transplanted patients, 51 were HCV-RNA negative for >4 weeks before LT (SVR12: 88%) and 49 negative for <4 weeks or still viraemic at transplant: 34 patients continued treatment after LT (bridging therapy) (SVR12: 88%), while 15 stopped treatment (SVR12: 53%). 98 patients completed SOF/R without LT (SVR12: 73%). In patients with advanced decompensated cirrhosis (basal MELD ≥15 and/or C-P ≥B8), a marked improvement of the scores occurred in about 50% of cases and almost 20% of decompensated patients without HCC reached a condition suitable for inactivation and delisting.These real-life data indicate that in waitlisted patients: (i) bridging antiviral therapy can be an option for patients still viraemic or negative <4 weeks at LT; and (ii) clinical improvement to a condition suitable for delisting can occur even in patients with advanced decompensated cirrhosis.

Sofosbuvir

Compassionate Use

Hepatitis C

10.1111/liv.13588

Cite

Citations (7)

Meta-analysis of trials for variceal bleeding

Hepatology (2002)

Gennaro D’Amico Valeria Criscuoli Daniela Filì Filippo Mocciaro Luigi Pagliaro

10.1053/jhep.2002.34737

Cite

Citations (39)